Clinical Trials Directory

Trials / Completed

CompletedNCT00410020

Arrhythmia Prevention With an Alpha-Linolenic Enriched Diet

Secondary Prevention of Atrial Fibrillation With an Alpha-Linolenic Enriched Diet : a Randomized Study

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
130 (planned)
Sponsor
Assistance Publique - Hôpitaux de Paris · Academic / Other
Sex
All
Age
18 Years – 77 Years
Healthy volunteers
Not accepted

Summary

An alpha linolenic acid (ALA) rich diet in the Lyon Diet Heart Study reduced sudden cardiac deaths possibly by reducing cardiac arrhythmias and ventricular fibrillation (Lancet 1994). Since then, there has been a growing interest in ALA, ω-3 fatty acid family precursor, as a cardioprotective nutrient. Much of the interest has focused on the potential antiarrhythmic effect of longer chain ω-3 fatty acids, DHA and EPA, derived from fish. We therefore concluded it important to test wether vegetable source ω-3 also had antiarrhythmic effects, as shown in animals by Leaf and McLennan, since this might also explain the beneficial effects seen on cardiovascular mortality in the Lyon Diet Heart Study.

Detailed description

Objective: To determine the effect of an ALA rich diet in reducing recurrence of atrial fibrillation as a further example of a cardiac arrhythmia. Design: Randomized parallel design efficacy study. Setting: Three university hospital centers in the Bordeaux region, France. Patients: 98 patients randomized immediately after successful atrial fibrillation electrical cardioversion. Intervention: A canola margarine and oil, versus a conventional diet (control), with a one year follow-up. Main outcome measure: Length of time to first recurrence of atrial fibrillation. Significance: If ALA is antiarrhythmic, this action may explain its cardioprotective effect in clinical trials and cohort studies.

Conditions

Interventions

TypeNameDescription
BEHAVIORALAlpha-linolenic enriched diet

Timeline

Start date
1999-06-01
Completion
2003-06-01
First posted
2006-12-12
Last updated
2006-12-12

Locations

3 sites across 1 country: France

Source: ClinicalTrials.gov record NCT00410020. Inclusion in this directory is not an endorsement.